Cautious Outlook on Teradyne: Sell Rating Amid Uncertainties and Overly Optimistic Market Estimates

Shane Brett CFA, an analyst from Morgan Stanley, maintained the Sell rating on Teradyne (TER – Research Report). The associated price target remains the same with $112.00.

Shane Brett CFA has given his Sell rating due to a combination of factors affecting Teradyne’s stock. The company is currently viewed as a ‘show me’ story, meaning that investors are waiting for more concrete evidence of future performance before making investment decisions. The upcoming Analyst Day is not expected to provide significant new information that would sway investor sentiment either positively or negatively.
Brett notes that while there is optimism for a cyclical recovery in 2026, current market estimates may be overly optimistic, particularly in light of the inconsistent revenue guidance for the years 2025, 2026, and 2028. Additionally, there are concerns about the declining market share in key segments like Auto/Industrial and NAND, as well as questions about the profitability and synergies of Teradyne’s robotics division. These uncertainties contribute to the cautious stance and the decision to maintain a Sell rating until more favorable data points emerge.